iPSC Archives | Page 3 of 15

Non-Commercial Organizations Developing iPSC Therapies

July 16, 2019 By Cade Hildreth (CEO) Leave a Comment

There are diverse and ever-growing number of commercial entities supporting the development of induced pluripotent stem cell (iPSC) therapies. However, there are also government and academic entities who are pursuing therapeutic progress with the cell type.

The most notable institutions working toward this goal are:

RIKEN Center in Kobe, Japan
Kyoto University in Kyoto, Japan
California Institute for Regenerative Medicine (CIRM) in California, USA

Each of these important institutions and their contributions to the development of new iPSC therapies is presented below.
[Read more…]

FUJIFILM CDI: A New Behemoth is Entering the Cell Therapy CDMO Market

June 14, 2019 By Cade Hildreth (CEO) Leave a Comment

A new behemoth is entering the cell therapy CDMO market, FUJIFILM Cellular Dynamics (FUJIFILM CDI). CDMOs are companies that provide manufacturing services to cell and gene therapy companies on a contract basis. In some cases, they may also support product development, clinical trial support, or commercial supply.

FUJIFILM Cellular Dynamics, Inc. (FCDI), a US subsidiary of FUJIFILM Corporation, will be spending $21M to open a new cGMP-compliant production facility in Madison, Wisconsin. According to FCDI’s January 2019 announcement, the facility will support FCDI’s internal cell therapeutics pipeline, as well as serve as a Contract Development and Manufacturing Organization (CDMO) for iPS cell products. [Read more…]

Fate Therapeutics to Launch First U.S. Clinical Trial of iPSC-derived Cell Product

December 3, 2018 By Cade Hildreth (CEO) Leave a Comment

The U.S. FDA has allowed Fate Therapeutics’ Investigational New Drug (IND) Application for FT500, positioning the company to launch the first clinical trial investigation of an iPSC-derived cell product within the United States.

FT500 is a universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line. Fate Therapeutics broke this exciting news in an announcement released November 30, 2018. [Read more…]

iPSC Market Accelerated by Clinical Studies in Japan, Australia, UK, and U.S.

December 2, 2018 By Cade Hildreth (CEO) 1 Comment

Growth of the iPSC market is supported by an increasing number of clinical studies that are investigating the therapeutic potential of iPSC-derived cell therapy products. Induced pluripotent stem cells (called iPSCs or iPS cells) are a type of stem cell that can become any cell within the human body, giving them enormous potential for use within regenerative medicine. [Read more…]

ORIG3N, Producing Patient-Specific iPS Cells – Interview with Robin Smith, CEO

November 12, 2018 By Cade Hildreth (CEO) Leave a Comment

ORIG3N, a biotechnology start-up headquartered in Boston, is attracting global attention for several reasons. First, it has created the world’s largest blood cell repository. ORIG3N is using these blood cells to produce patient-specific induced pluripotent stem cells (iPSCs), allowing the cells to be ever-renewing and giving rise to a living database of humanity known as LifeCapsule.

Second, the company has two other business segments, called LifeProfile and LifeSystems. These business units of ORIG3N help people to better understand the links between their genes and how their minds and bodies work.

Third, ORIG3N has identified HLA Superdonor matches for 90% of the U.S. population, positioning it to be custodians of this “first of a kind asset on planet earth.”

[Read more…]

The most notable institutions working toward this goal are:

BioInformant's World-Class Clients